Malcolm S. Taub - 15 Dec 2021 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Director
Issuer ticker: BCLI
Reported as of: 15 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2021, 16:04:15 UTC
Prior SEC filing: 10 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Malcolm Taub

Key filing fact

Malcolm S. Taub filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 17 Dec 2021.

Key facts

This page summarizes Malcolm S. Taub's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Dec 2021, 16:04.

Change

Previous filing in this sequence was filed on 10 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value: $0
Shares: +12,000
Change %: +18%
Price: $0.000000
Shares after: 77,332
Date: 15 Dec 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.